Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus TYLENOL W CODEINE NO 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus TYLENOL W CODEINE NO 1.
QDOLO vs TYLENOL W/ CODEINE NO. 1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Codeine is a prodrug that undergoes O-demethylation via CYP2D6 to morphine, which acts as a μ-opioid receptor agonist. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and modulating pain perception.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
Adult: 1-2 tablets (acetaminophen 300 mg/codeine 8 mg per tablet) orally every 4-6 hours as needed; maximum 8 tablets per day. Route: oral. Frequency: every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Acetaminophen: 2-3 hours; Codeine: 2.5-3.5 hours; Morphine (active metabolite): 2-4 hours. Terminal half-life prolonged in hepatic impairment or elderly.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Renal: ~70-80% of codeine as inactive metabolites (codeine-6-glucuronide, norcodeine, morphine) and ~5-10% as unchanged codeine; ~5-15% of acetaminophen as unchanged drug. Biliary/fecal: minimal (<5% for both).
Category C
Category D/X
Opioid Agonist
Opioid Agonist